NEW YORK (GenomeWeb News) – Epigenomics and the Abbott Molecular business of Abbott have expanded their collaboration and amended an earlier licensing deal aimed at developing molecular diagnostic products.
The firms began collaborating in September 2007 on development of a colorectal cancer diagnostic based on Epigenomics' intellectual property.
Under the amended deal announced today, Abbott has obtained additional non-exclusive licenses to Epigenomics’ proprietary DNA methylation technology to develop and commercialize a blood test for colorectal cancer detection based on Epigenomics’ Septin 9 biomarker.
In addition, Abbott gains access to blood samples collected in the ongoing Presept clinical study sponsored by Epigenomics. Abbott will use the samples for clinical validation of a Septin 9 in vitro diagnostic test, which the firms intend to file for US regulatory clearance in 2010. They also plan to release a CE-marked test, which will run on Abbott’s m2000 molecular diagnostics instrument, next year.
In return for the license, Abbott will pay Epigenomics a technology license fee, certain milestone payments, and reimbursements associated with the Presept study, as well as royalties based on sales of the Septin 9 test.